New Treatment Strategy Offers Hope To RA Patients
Rheumatoid arthritis (RA) patients who failed to respond to initial treatment with rituximab (RTX) (a chimeric monoclonal antibody against the protein CD20) can still be successfully re-treated with a second course of RTX after six months, according to the results of a new study presented today at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark.
In the study, 72% of RA patients who did not respond to initial treatment with RTX achieved improved disease activity scores (DAS28) and EULAR responses when re-treated with RTX after six months. In some cases the responses were dramatic, with patients achieving complete remission for a year or longer.
Although the exact cause of rheumatoid arthritis is not complete understood, it is believed to involve B cells (part of the immune system) that become abnormal and cause the immune system to attack the joints. Rituximab works by killing B cells, removing the cause of the inflammation. B cells are gradually replaced over the next 6 to 12 months by new cells from the bone marrow. Rituximab is effective in approximately two thirds to three quarters of patients treated, however in some patients it is ineffective. Under current licensing rituximab is generally used only when all other treatments (such as methotrexate or anti-TNF agents) have failed. This means that patients that fail to respond to rituximab usually have no other treatment available to them. Although new drugs are being developed for RA, this study demonstrates why rituximab treatment fails in some patients, and how it can be used more effectively to treat patients with the worst disease.
The study used a technique called highly sensitive flow cytometry that can accurately measure the very small numbers of B cells that remain in the system after treatment with rituximab. Initial studies with rituximab in RA seemed to show that all B cells were completely removed in all patients, even those that failed to show an improvement in symptoms and signs of arthritis after treatment. Highly sensitive flow cytometry shows that B cells are not always completely removed, and almost all patients that fail to improve after rituximab have incomplete B cell depletion. In addition, patients in whom B cell depletion is incomplete have higher numbers of certain B cells (preplasma and memory B cells) before treatment.
In the study, 104 patients (with complete data) were treated with rituximab and depletion assessed using highly sensitive flow cytometry. 90% of patients who did not respond clinically to treatment had incomplete B cell depletion. Non-response could also be predicted by higher baseline levels of memory B cells (p= 0.027) and preplasma cells (p= 0.006). 25 patients who had failed to respond to an initial treatment with rituximab were retreated six months later. At this stage B cells had not yet recovered to pre-treatment levels. Re-treating with a second course of rituximab resulted in greater B cell depletion, with 48% now achieving complete depletion (p = 0.02). 72% of these patients then responded clinically, as defined by a moderate or better EULAR response. 32% had a good response and 16% were in remission. A significant improvement was observed in DAS28* (p < 0.001) and all its components of DAS28.
Dr Edward Vital of Leeds Institute of Molecular Medicine, University of Leeds, UK, who led the study, said: "Although rituximab can be effective in RA, around a third of patients fail to achieve an adequate response the first time they are treated. Our study has shown that re-treating patients at a specific stage can enhance clinical responses to a level equal to those who fully respond to the RTX course at first administration. This provides hope for patients who are classified as non-responders and would normally have limited other treatment options. The next question is whether patients who have predictors of poor response could be treated more intensively from the outset, for example with a different dose of rituximab."